COLT FAST-TRACKS THE DELIVERY OF NEW SERVICES WITH CISCO SEGMENT ROUTING AND ETHERNET VPN

LONDON, April 5 (Bernama-GLOBE NEWSWIRE) -- Cisco and Colt Technology Services announced today that they have successfully achieved a key milestone in upgrading Colt's pan-European, US and Asian packet network. This lays the foundation for the Colt IQ Network to deliver further differentiated, high-bandwidth connectivity solutions.

Cisco and Colt revealed in December 2016 that they were working on a system-wide, multiple 100Gbps upgrade to Colt's IQ Network. This will enable it to rapidly deliver high-performance connectivity for cloud-scale, business-critical applications to its enterprise, carrier and web-centric customers. By combining segment routing and Ethernet VPN (EVPN), Colt’s IQ Network now benefits from faster convergence time, increased network availability and resiliency for any topology, while enabling the service provider to deliver high-bandwidth solutions much faster.

http://mrem.bernama.com/viewsm.php?idm=31610

CROWNBIO TO SHOWCASE SCIENTIFIC EXPERTISE IN PRECLINICAL DRUG DEVELOPMENT AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE

SAN DIEGO, April 5 (Bernama-GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year’s American Association for Cancer Research’s International Conference (AACR) in Chicago, IL on April 14^th - 18^th.

CrownBio’s scientists will present more than a dozen scientific posters describing their latest efforts to revolutionize preclinical development of cancer treatments. These scientific posters will demonstrate the combined power of CrownBio’s integrated oncology platform to advance oncology pipelines using their exhaustive patient-derived xenograft (PDX) collection, innovative humanized tumor models and three dimensional ex vivo cultures that recapitulate the in vivo tumor microenvironment. Featured work will show data from novel models that enable precise evaluation of new cancer therapeutics, including bi-specific T-cell engagers (BiTEs), targeted cancer immunotherapies and combinatory immunotherapies.

“I am excited to share Crown Bioscience’s cutting-edge research with colleagues at AACR,” said Dr. Henry Li, Crown Bioscience’s Vice President of Translational Oncology. “The data presented will exhibit the utility of our clinically relevant solutions to identify critical biomarkers and improve preclinical evaluation of cancer therapies.”

“Crown Bioscience is honored to play a leading role in presenting opportunities for scientific advancements at AACR,” said Laurie Heilmann, Chief Business Officer. “The work of our dedicated scientific team exemplifies Crown Bioscience’s commitment to helping researchers solve global health challenges through continued innovation of our scientific translational platform.” 

http://mrem.bernama.com/viewsm.php?idm=31606

ANNOUNCING ACE HOTEL KYOTO IN PARTNERSHIP WITH ARCHITECT KENGO KUMA AND NTT UD

Opening Winter 2019

Kyoto, Japan, April 6 (Bernama-GLOBE NEWSWIRE) -- ACE HOTEL TO OPEN FIRST JAPANESE OUTPOST IN KYOTO

Since the beginning of Ace, we’ve dreamt of Japan. We’ve spent decades admiring Japanese culture and craftsmanship, collaborating from afar with Japanese artists and brands whose work we love — BEAMS, Porter, Isetan, Takahiro Miyashita of Number (N)ine, Kenzo Minami, Hender Scheme and Traveler’s Company, to name a few, hoping for the chance to put down roots.

Now, we’re proud to announce we’re partnering with NTT Urban Development Corporation for Ace Hotel Kyoto, a new cultural hub as part of the redevelopment of ShinPuhKan. Designed in part by the famed architect Kengo Kuma, Ace Hotel Kyoto will open in Winter 2019 in an area with a valuable industrial and imperial legacy. Kuma’s designs blend new with old, incorporating renovations of the historic building — erected in the mid 1920s as the Kyoto Central Telephone Office — into the new build.

http://mrem.bernama.com/viewsm.php?idm=31618

FOOMA JAPAN 2018, LARGEST TRADE SHOW OF "FOOD MACHINERY" AND "FOOD-PROCESSING TECHNOLOGY" IN ASIA, SET FOR JUNE 12-15, 2018, IN TOKYO, JAPAN

TOKYO, Apr. 9, 2018 /Kyodo JBN-AsiaNet/ --
 
- Over 100,000 Visitors; Asia's Largest Trade Show for Food Technologies -
 
FOOMA JAPAN (International Food Machinery & Technology Exhibition), will organize the largest trade show in Asia for food technologies -- FOOMA JAPAN 2018 -- at Tokyo Big Sight in Tokyo from Tuesday, June 12, to Friday, June 15, 2018.
 
The exhibition will bring together companies from all the fields of food production processes -- from raw material processing to packaging and logistics with a focus on food production and processing machinery -- to form a comprehensive trade show of food machinery and food-processing technology.
 
This annual exhibition, which has a long history and tradition, marks its 41st show this year. More than 700 companies will be exhibiting at this huge-scale trade show, one of the largest in Asia. More than 100,000 people will attend the exhibition from Japan and abroad, seeking Japan's excellent food-manufacturing and processing machinery.
 
(Photo: https://kyodonewsprwire.jp/img/201803292477-O1-dwC8XVZ6)
 
- From Japan to the world. Encompassing all food-related technologies
FOOMA JAPAN 2018 brings together cutting-edge products, technologies, services and information related to food under the theme of "Food Technology Unlimited." It covers all food-related technologies such as food-processing technology, safety and hygiene technology, energy conservation and environment technology for productivity improvement, greater efficiency, and better quality.
 
You can expect further improvements in your food-manufacturing and processing issues by watching demonstrations, touching and tasting, just as if you were at a food factory. Many fields are on exhibition, including machines that manufacture Japanese food such as sushi and noodles popular across the world and robot systems for food production that utilize IoT and AI, etc., to automate the production process.
 
- On-site support for overseas visitors provided
FOOMA JAPAN has substantial services for visitors from overseas. In the exhibition hall, persons who can speak English, Chinese, Korean and other foreign languages wear a "bilingual badge" on their chests and offer language support. The Information Desk is staffed by people who respond to inquiries in English, Chinese and Korean. You can also relax at the International Lounge, which offers free drinks.
 
Scenes of FOOMA JAPAN 2017, as well as exhibitor names and exhibited products, are published on the official website, where you can appreciate the huge scale of one of Asia's largest exhibitions.
 
FOOMA JAPAN 2018 visitor preregistration has started on the official website from April 2, 2018. Hotel reservations are also possible on the site.
 
Please check the official website for the latest information on a wide range of services.
https://www.foomajapan.jp/english/index.html
 
About organizer
The Japan Food Machinery Manufacturers' Association (FOOMA) was established in 1948 (received recognition as a corporation in March of 1967 by the Ministry of International Trade and Industry, currently the Ministry of Economy, Trade and Industry) to develop the Japanese food machinery industry.
 
FOOMA is organized by leading Japanese food machinery manufacturers and a sole association for the Japanese food machinery industry. FOOMA has over 400 members and focuses not only on development of the Japanese food machinery industry but also on contribution to healthy life in the whole world by Japanese food technology.
 
Source: The Japan Food Machinery Manufacturers' Association
 
--BERNAMA

http://mrem.bernama.com/viewsm.php?idm=31624

Berkshire Hathaway Specialty Insurance introduces two policies in Asia

KUALA LUMPUR, April 9 (Bernama) -- Berkshire Hathaway Specialty Insurance Company (BHSI) today introduced two policies in Asia, Executive First Private Company Portfolio and Executive First Nonprofit Organisation Portfolio.

The Private Company Portfolio extends coverage to both individuals and the entity and includes Directors and Officers Liability, Employment Practices Liability and Employee Dishonesty coverages, a statement said.

The Nonprofit Organisation Portfolio offers similar coverages, with the addition of Professional Indemnity protection to address the specific needs of a nonprofit organisation including coverage for corrective actions to help nonprofit organisations mitigate potential losses and avoid claims.

The key features include pre-investigations cost coverage, court attendance coverage and advancement of defence costs.

"Both policies reflect our commitment to providing the simple, concise solutions customers need for multifaceted management liability risks in today's world," said senior manager, Executive and Professional Lines, BHSI Hong Kong, Nero Shiu.

Assistant vice-president, Executive and Professional Lines, BHSI Singapore, Edwin Sim said the new policies address the full range of claims private companies, nonprofit organisations and their directors and officers may encounter today.

BHSI provides commercial property, casualty, healthcare professional liability, executive and professional lines, surety, travel, programs, medical stop loss and homeowners insurance. More information can contact info@bhspecialty.com

--BERNAMA

SINGAPORE A GLOBAL INNOVATION CHAMPION, SAYS CTA

ARLINGTON, Va., April 6 (Bernama-BUSINESS WIRE) -- A new global ranking from the Consumer Technology Association (CTA) identifies Singapore is one of 13 countries earning the designation of 2018 Innovation Champion. CTA’s inaugural Innovation Scorecard identifies critical areas of national policy that spur innovation and reveals the areas in which countries may be stunting their own futures and economic growth.

“The trend lines are clear – Innovation is encouraged where governments, such as Singapore’s, are hospitable to new ideas, where people enjoy great freedom and clean environments and where innovators are embraced,” said Gary Shapiro, CEO and president, CTA. “Countries’ futures are tied to innovation, because it will bolster economic growth and provide future generations with the jobs they want. Graduates entering the work force today don’t necessarily want to stay in the factory jobs of previous generations – they want to use their creativity and curiosity to build brighter futures worldwide.”

CTA, the largest U.S. tech trade association, conducted a comparative analysis of 38 countries and the European Union. In addition to Singapore, CTA’s Scorecard named Australia, Austria, Denmark, the United Kingdom, Sweden, United States, Portugal, Finland, New Zealand, Canada, the Czech Republic and the Netherlands as global Innovation Champions.

Singapore earned the fourth-highest composite score in the Scorecard. It was also one of only three countries to receive an ‘A’ grade or higher in Diversity, with the highest percentage of immigrants as a share of its population — a remarkable 45.4 percent. The report also notes Singapore makes no secret of its desire to become a leader in self-driving vehicles, hosting the first-ever self-driving taxi service in 2016.

Although Singapore scores very well in the Scorecard, the country could take actions to be more hospitable to the sharing economy. Would-be ridesharing drivers are subject to unnecessary licensing and testing requirements, and short-term renters face federal length-of-stay limits.

http://mrem.bernama.com/viewsm.php?idm=31617

NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE

- Neuralstem Releases Full Data Set for NSI-189 MDD Trial Showing Patient Rated Outcome and Cognitive Benefits

- Nature Medicine Paper Demonstrates Benefit of NSI-566 on Paralysis in Non-Human Primates

GERMANTOWN, Md., April 3 (Bernama-GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the year ended December 31, 2017.

“We remain committed to the development of NSI-566, our lead stem cell therapy candidate, and NSI-189 for major depressive disorder (MDD), which we believe offer novel modalities of treatments for patients that are not effectively treated by current therapies,” said Rich Daly, President & CEO. “We are preparing for the initiation of a clinical trial for NSI-566 in chronic stroke in China and have targeted mid-2018 to begin dosing. The recent findings of NSI-566 that were published in Nature Medicine were very encouraging, demonstrating NSI-566 led to a measurable improvement in forelimb function in injured animals. We look forward to continuing to explore its utility as a potential treatment for paralysis associated with spinal cord injuries.”

“We plan to formulate the clinical development path for NSI-189 in MDD after our meeting with the U.S. Food and Drug Administration which we expect to occur in the second half of 2018. NSI-189 may offer cognitive benefits in addition to antidepressant effects, which would distinguish it from other approved treatments,” Mr. Daly continued.  

Clinical Highlights for Lead Clinical Programs

NSI-566, is a spinal cord-derived neural stem cell line that is being evaluated to treat paralysis associated with stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI).

• The publication of a manuscript in Nature Medicine demonstrated that NSI-566 provided meaningful improvement in forelimb function in a non-human primate model following acute spinal cord injury. The study was performed at the California National Primate Research Center at University of California, Davis by Mark H. Tuszynski, MD, PhD, Professor of Neurosciences, Director of the Center for Neural Repair, an Attending Neurologist at the University of California, San Diego (UCSD). The full manuscript can be found here.

• In March, the Journal of Neurotrauma published preclinical data on NSI-566 spinal cord-derived neural stem cells in a study entitled, “Amelioration of penetrating ballistic-like brain injury induced cognitive deficits after neuronal differentiation of transplanted human neural stem cells.” These data showed robust engraftment and long-term survival of NSI-566 post transplantation in a rat model of penetrating ballistic-like brain injury. These are the first data from the 4-year proof-of-concept research program, funded by the United States Department of Defense, for NSI-566 in traumatic brain injury. The study was led by Ross Bullock, M.D., Ph.D., The Miami Project to Cure Paralysis, University of Miami School of Medicine. 

NSI-189, a benzylpiperazine-aminopyridine, in clinical development for MDD and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

http://mrem.bernama.com/viewsm.php?idm=31583